ERYP.PA
Price:
$0.801
Market Cap:
$15.68M
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.[Read more]
Industry
Biotechnology
IPO Date
2013-05-07
Stock Exchange
EURONEXT
Ticker
ERYP.PA
According to ERYTECH Pharma S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -80.10. This represents a change of 9.33% compared to the average of -0.85 of the last 4 quarters.
The mean historical PE Ratio of ERYTECH Pharma S.A. over the last ten years is -8.70. The current -80.10 PE Ratio has changed 92.01% with respect to the historical average. Over the past ten years (40 quarters), ERYP.PA's PE Ratio was at its highest in in the December 2022 quarter at 3.57. The PE Ratio was at its lowest in in the June 2022 quarter at -8.48.
Average
-8.70
Median
-2.43
Minimum
-49.90
Maximum
-0.85
Discovering the peaks and valleys of ERYTECH Pharma S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 5.25%
Maximum Annual PE Ratio = -0.85
Minimum Annual Increase = -98.30%
Minimum Annual PE Ratio = -49.90
Year | PE Ratio | Change |
---|---|---|
2023 | -0.85 | -98.30% |
2022 | -49.90 | 5.25% |
2021 | -0.93 | -47.66% |
2020 | -1.78 | -7.01% |
2019 | -1.92 | -34.61% |
2018 | -2.93 | -53.24% |
2017 | -6.27 | 25.89% |
The current PE Ratio of ERYTECH Pharma S.A. (ERYP.PA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-17.23
5-year avg
-11.08
10-year avg
-8.70
ERYTECH Pharma S.A.’s PE Ratio is less than Innate Pharma S.A. (-3.27), less than Nanobiotix S.A. (-3.89), less than Genfit S.A. (131.68), less than Adocia SA (-2.83), less than DBV Technologies S.A. (-0.76),
Company | PE Ratio | Market cap |
---|---|---|
-3.27 | $111.39M | |
-3.89 | $135.34M | |
131.68 | $187.23M | |
-2.83 | $109.78M | |
-0.76 | $71.98M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ERYTECH Pharma S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ERYTECH Pharma S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ERYTECH Pharma S.A.'s PE Ratio?
How is the PE Ratio calculated for ERYTECH Pharma S.A. (ERYP.PA)?
What is the highest PE Ratio for ERYTECH Pharma S.A. (ERYP.PA)?
What is the 3-year average PE Ratio for ERYTECH Pharma S.A. (ERYP.PA)?
What is the 5-year average PE Ratio for ERYTECH Pharma S.A. (ERYP.PA)?
How does the current PE Ratio for ERYTECH Pharma S.A. (ERYP.PA) compare to its historical average?